An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers

Clin Cancer Res. 2022 Jun 13;28(12):2477-2479. doi: 10.1158/1078-0432.CCR-22-0341.

Abstract

Central nervous system (CNS) metastases constitute a challenge for the design of anaplastic lymphoma kinase (ALK) fusion-positive lung cancer trials. The ASCEND-7 study of ceritinib demonstrates the feasibility of broadening CNS eligibility criteria to include symptomatic brain and leptomeningeal disease and highlights design features that contemporary trials will need to incorporate. See related article by Chow et al., p. 2506.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Brain / pathology
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Central Nervous System
  • Central Nervous System Neoplasms* / diagnosis
  • Humans
  • Lung Neoplasms* / pathology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines
  • Receptor Protein-Tyrosine Kinases
  • Sulfones

Substances

  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sulfones
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
  • ceritinib